Umea Universitet

Diabetes Drug Pioglitazone Shows Promising Anti-Tumor Effects in Prostate Cancer

13 days ago

• Researchers from the Medical University of Vienna have discovered that PPAR𝛾, a protein targeted by type 2 diabetes medications, can influence prostate cancer cell growth. • The diabetes drug pioglitazone was found to inhibit tumor cell growth and metabolism in prostate cancer, suggesting potential repurposing opportunities for existing diabetes treatments. • Initial clinical observations indicate that prostate cancer patients with diabetes who received PPAR𝛾 agonists showed no cancer relapse during the study period, warranting further investigation.

SBRT Shows Non-Inferiority to Standard Radiotherapy in Localized Prostate Cancer

6 months ago

• A phase 3 trial, PACE-B, reveals that five-fraction stereotactic body radiotherapy (SBRT) is non-inferior to conventional radiotherapy for low- to intermediate-risk localized prostate cancer. • The 5-year incidence of freedom from biochemical or clinical failure was 95.8% in the SBRT group and 94.6% in the control group, indicating comparable cancer control outcomes. • SBRT offers a reduced treatment duration, potentially alleviating the burden on healthcare systems while maintaining favorable cancer control without hormonal treatment. • While genitourinary adverse effects were slightly higher in the SBRT group, the overall safety profile was acceptable, supporting SBRT as a viable alternative to standard radiotherapy.